Saunders C Hsu, M.D., MPH
Investigator
Saunders C. Hsu, MD, MPH is a pediatric hematologist-oncologist currently practicing with Sutter Medical Group. Dr. Hsu has over two decades of experience in pediatric hematology and oncology, previously serving with Northern California Children’s Hematology/Oncology Medical Group from 2006 to 2025.
He completed his pediatric residency at SUNY Brooklyn Health Science Center and fellowship training in hematology/oncology at Oregon Health & Science University, where he also earned a Master of Public Health.
Dr. Hsu received his medical degree from the University of Illinois College of Medicine and holds a bachelor’s degree in chemical engineering from the Massachusetts Institute of Technology.
His career includes diverse clinical and research experiences, including global health work in Thailand and service as a physician in Alaska, as well as laboratory research focused on cancer diagnostics and immunology.
Clinical trials
Triptorelin and Protection of Ovarian Reserve in Adolescents and Young Adults With Cancer
Status: Open to Enrollment
- Clinical trial
Neoadjuvant Hodgkin Lymphoma COG AHOD2131
A Randomized Phase 3 Interim Response Adapted Trial Comparing Standard Therapy With Immuno-oncology Therapy for Children and Adults With Newly Diagnosed Stage I and II Classic Hodgkin Lymphoma
Status: Open to Enrollment
- Clinical trial
Neoadjuvant Neuroblastoma ANBL2131
A Phase 3 Study of Dinutuximab Added to Intensive Multimodal Therapy for Children With Newly Diagnosed High-Risk Neuroblastoma
Status: Open to Enrollment
- Clinical trial
Neoadjuvant Pediatric Leukemia AALL1821
A Phase 2 Study of Blinatumomab (NSC# 765986) in Combination With Nivolumab (NSC # 748726), a Checkpoint Inhibitor of PD-1, in B-ALL Patients Aged >/= 1 to < 31 Years Old With First Relapse.
Status: Open to Enrollment
- Clinical trial
Pediatric B-Lymphoblastic Leukemia COG AALL1732
A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (NSC#: 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-LLyLy
Status: Open to Enrollment